Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa trial of Ampligen (rintatolimod) in combination with checkpoint inhibitors for the treatment of advanced urothelial cancer, renal cell carcinoma and Melanoma (Second line therapy or greater, combination therapy)

Trial Profile

A Phase IIa trial of Ampligen (rintatolimod) in combination with checkpoint inhibitors for the treatment of advanced urothelial cancer, renal cell carcinoma and Melanoma (Second line therapy or greater, combination therapy)

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2018

At a glance

  • Drugs Rintatolimod (Primary) ; Immunotherapies
  • Indications Bladder cancer; Malignant melanoma; Renal cell carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2018 New trial record
    • 10 Oct 2018 According to Hemispherx Biopharma media release, this trial will be led by Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and Professor of Oncology in the Department of Medicine and Co-Leader of the Tumor Immunology and Immunotherapy Program at Roswell Park, in collaboration with Mateusz Opyrchal, MD, PhD, of the Roswell Park Department of Medicine.
    • 10 Oct 2018 According to Hemispherx Biopharma media release, this trial is being conducted under a Clinical Trial Agreement between the company and the Roswell Park Comprehensive Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top